Back to search results

Lung Ultrasound for Respiratory Distress Syndrome in Premature Infants

This study is looking at whether using a lung ultrasound score can help doctors decide more quickly when to give surfactant to premature babies with Respiratory Distress Syndrome (RDS). RDS is a common breathing problem in premature infants. The study will involve 100 infants born between 27 and 34 weeks of pregnancy who need breathing support and have RDS or are at risk for it. The main goal is to see if using lung ultrasound leads to faster surfactant administration. Researchers will also check if this approach improves how well babies breathe in the short term, such as reducing the need for breathing machines or oxygen. This study is currently recruiting participants.

Study design
This is a prospective randomized controlled study involving 100 infants. There will be 67 infants in the group receiving the lung ultrasound-guided care and 33 in a control group.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes, like time to lung ultrasound and time to surfactant administration, are assessed up to 1 week of life.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07442669

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

Recruiting
NAAges 27–34InterventionalTreatment
Hackensack Meridian Health
~100 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Lung ultrasound

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to Lung Ultrasound
Measured over From date of birth to until the date/time of the lung ultrasound or date of death from any cause, assessed up to 1 week of life
+1 more outcome measured

Conditions

Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome in Premature Infant

Explore related trials

Respiratory Distress Syndrome

NCT07442669

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Hackensack Univeristy Medical Center

    Hackensack, New Jerseyno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sandy Cheung, DO · PRINCIPAL_INVESTIGATOR · Hackensack Meridian Health

Who to contact

Jeanette Buljevich Haugh
[email protected]
5519963457
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Inborn at 27 0/7 to 34 6/7 weeks of gestational age
Spontaneously breathing at birth but requiring non-invasive respiratory support
RDS diagnosed on chest x-ray (diffuse, bilateral, fine granular opacities in lungs, air bronchograms) or were at risk of developing RDS

Exclusion

Outborn
Endotracheal intubation in the delivery room or within 2 hours of life
Surfactant in the delivery room as part of advanced resuscitation
Presence of major congenital malformations or chromosomal anomalies
Hydrops fetalis
Inherited disorders of metabolism
Air leak syndrome (pneumothorax, pneumomediastinum) prior to surfactant administration, congenital diaphragmatic hernia, congenital pneumonia, meconium aspiration syndrome
Infants in extremis not expected to survive

What this trial measures

  • Time to Lung UltrasoundFrom date of birth to until the date/time of the lung ultrasound or date of death from any cause, assessed up to 1 week of life

    To assess the feasibility of the lung ultrasound, this metric measures the elapsed time from birth to the administration of the lung ultrasound.

  • Time to surfactant administration via LISA methodFrom date of birth to until the date/time of first documented progression (surfactant administration) or date of death from any cause, assessed up to 1 week of life

    Neonates who underwent evaluation with lung ultrasound and received a LUS of 6 or greater in \< 28 week gestation and total LUS of 8 or greater in \> 28 week gestation will receive exogenous surfactant via the LISA method. The time to surfactant administration will be calculated from time of birth to time receiving therapy in hours.